Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...
On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...
Nuclear medicine has made significant strides in the field of oncology, particularly through the development of molecular probes and targeted radiopharmaceuticals. This progress has transformed cancer ...
InvestorsHub on MSN
BullFrog AI signs commercial agreement with top global pharmaceutical company to identify drug targets for depression
BullFrog AI Holdings, Inc. (NASDAQ:BFRG), a technology company focused on applying artificial intelligence and machine ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results